This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Teva Pharmaceutical Industries Limited's CEO Discusses Q1 2012 Results - Earnings Call Transcript

Teva Pharmaceutical Industries Limited (TEVA)

Q1 2012 Earnings Call

May 09, 2012 8:30 am ET

Executives

Kevin Mannix - Director of Investor Relations - Teva North America

Shlomo Yanai - Chief Executive Officer and President

Eyal Desheh - Chief Financial Officer

Jeremy Levin -

William S. Marth - Chief Executive Officer of Teva Americas and President of Teva Americas

Robert Koremans -

Michael Hayden -

Unknown Executive -

Gerard W.M. Van Odijk - Former Chief Executive Officer of Teva Europe and President of Teva Europe

Analysts

Christopher Schott - JP Morgan Chase & Co, Research Division

Aaron Gal - Sanford C. Bernstein & Co., LLC., Research Division

Traver A. Davis - Piper Jaffray Companies, Research Division

Corey B. Davis - Jefferies & Company, Inc., Research Division

David G. Buck - The Buckingham Research Group Incorporated

Gregory B. Gilbert - BofA Merrill Lynch, Research Division

Limor Gruber - Psagot Investment House Ltd., Research Division

Frank H. Pinkerton - SunTrust Robinson Humphrey, Inc., Research Division

Elliot Wilbur - Needham & Company, LLC, Research Division

Douglas D. Tsao - Barclays Capital, Research Division

Marc Goodman - UBS Investment Bank, Research Division

Florent Cespedes - Exane BNP Paribas, Research Division

Jason M. Gerberry - Leerink Swann LLC, Research Division

Shibani Malhotra - RBC Capital Markets, LLC, Research Division

Presentation

Operator

Ladies and, gentlemen, thank you for standing by. Welcome to the Teva Pharmaceutical Industries Ltd. First Quarter 2012 Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded, May 9, 2012.

I'll now hand over the call to Mr. Kevin Mannix, VP, Head of Investor Relations. Mr. Mannix, would you like to begin?

1 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 16,102.38 -272.38 -1.66%
S&P 500 1,921.22 -29.91 -1.53%
NASDAQ 4,683.9190 -49.5780 -1.05%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs